Cleave Biosciences aims to create novel small molecules that work to control protein homeostasis in order to treat blood and solid cancers. Now, oncology giant…

The value of Neil Woodford’s Patient Capital Trust fell 10.8% as Circassia’s late-phase flop and the ongoing decline of Northwest Biotherapeutics hit home.

Life science VC firms have stumped up $25 million in a Series A raise for Cambridge, MA-based biotech Avrobio as it looks to take its gene therapy work into…

Bioniz Therapeutics is slated to start a Phase I trial for one of its cytokine inhibitors in partnership with the National Institutes of Health (NIH). Now, it’…

Specialty pharma InnoPharma was acquired by Pfizer a few years ago for up to $360 million. Now, the team behind that effort is at it again with another…

Unlikely IPO candidate Kadmon made it out in a tough IPO market amid swirling criticisms of its rather infamous current and former management, namely the…

Seattle startup Just Biotherapeutics has nabbed another $14 million to work on affordable biologics with a team lifted from Amgen as well as major backing…

The first spinoff from Cydan, an orphan disease incubator created by Pfizer Ventures and New Enterprise Associates, has nabbed $17 million to bump up its…